Pictet Asset Management SA Takes Position in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)

Pictet Asset Management SA bought a new stake in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTAGet Rating) in the second quarter, HoldingsChannel.com reports. The firm bought 29,629 shares of the biotechnology company’s stock, valued at approximately $1,401,000.

A number of other institutional investors also recently modified their holdings of the business. Signaturefd LLC raised its stake in Enanta Pharmaceuticals by 86.7% in the first quarter. Signaturefd LLC now owns 392 shares of the biotechnology company’s stock valued at $28,000 after purchasing an additional 182 shares in the last quarter. Nisa Investment Advisors LLC raised its stake in Enanta Pharmaceuticals by 164.1% in the second quarter. Nisa Investment Advisors LLC now owns 1,207 shares of the biotechnology company’s stock valued at $57,000 after purchasing an additional 750 shares in the last quarter. Captrust Financial Advisors raised its stake in Enanta Pharmaceuticals by 343.8% in the first quarter. Captrust Financial Advisors now owns 852 shares of the biotechnology company’s stock valued at $61,000 after purchasing an additional 660 shares in the last quarter. KBC Group NV acquired a new position in Enanta Pharmaceuticals in the first quarter valued at about $113,000. Finally, Mutual of America Capital Management LLC raised its stake in Enanta Pharmaceuticals by 6.9% in the first quarter. Mutual of America Capital Management LLC now owns 2,629 shares of the biotechnology company’s stock valued at $187,000 after purchasing an additional 170 shares in the last quarter. Institutional investors own 97.09% of the company’s stock.

Enanta Pharmaceuticals Price Performance

Enanta Pharmaceuticals stock opened at $45.44 on Wednesday. The business has a 50 day moving average of $48.33 and a 200-day moving average of $51.26. Enanta Pharmaceuticals, Inc. has a 1 year low of $37.59 and a 1 year high of $92.90. The company has a market capitalization of $941.74 million, a P/E ratio of -7.75 and a beta of 0.53.

Enanta Pharmaceuticals (NASDAQ:ENTAGet Rating) last released its quarterly earnings data on Monday, November 21st. The biotechnology company reported ($1.27) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.37) by $0.10. Enanta Pharmaceuticals had a negative return on equity of 32.42% and a negative net margin of 134.21%. The company had revenue of $20.32 million during the quarter, compared to the consensus estimate of $22.86 million. During the same quarter in the prior year, the firm posted ($1.22) earnings per share. The firm’s revenue was down 13.8% compared to the same quarter last year. Equities analysts anticipate that Enanta Pharmaceuticals, Inc. will post -6.01 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research firms recently commented on ENTA. Oppenheimer boosted their price target on Enanta Pharmaceuticals from $53.00 to $59.00 and gave the company a “market perform” rating in a research note on Wednesday, August 10th. SVB Leerink boosted their target price on Enanta Pharmaceuticals from $44.00 to $50.00 and gave the stock a “market perform” rating in a research note on Monday, August 1st. Royal Bank of Canada lowered their target price on Enanta Pharmaceuticals from $65.00 to $54.00 and set a “sector perform” rating for the company in a research note on Tuesday. JMP Securities reissued a “buy” rating and set a $96.00 target price on shares of Enanta Pharmaceuticals in a research note on Tuesday. Finally, StockNews.com started coverage on Enanta Pharmaceuticals in a research note on Wednesday, October 12th. They set a “hold” rating for the company. Four equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Enanta Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus target price of $68.71.

Enanta Pharmaceuticals Profile

(Get Rating)

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus.

Featured Articles

Want to see what other hedge funds are holding ENTA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Enanta Pharmaceuticals, Inc. (NASDAQ:ENTAGet Rating).

Institutional Ownership by Quarter for Enanta Pharmaceuticals (NASDAQ:ENTA)

Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.